09th week of 2009 patent applcation highlights part 48 |
Patent application number | Title | Published |
20090054283 | LUBRICATION OIL COMPOSITIONS - This invention relates to lubrication oil compositions comprising (i) a base fluid stock comprising (a) a PO3G fluid (a polytrimethylene ether glycol that is a fluid at ambient temperature) and (b) a PO3G ester fluid (an ester of a polytrimethylene ether glycol that is a fluid at ambient temperature), and (ii) one or more fuel oil additives. | 2009-02-26 |
20090054284 | LUBRICATION OIL COMPOSITIONS - This invention relates to lubrication oil compositions comprising (i) an acid ester (monoester and/or diester) of polytrimethylene ether glycol; and (ii) a vegetable oil lubricant. | 2009-02-26 |
20090054285 | Lubricant composition with low deposition tendency - Lubricant base oil blends and finished lubricating compositions having low deposition tendency are provided. The base oil blends consist essentially of about 20 wt % to about 80 wt %, based on the total weight of the blend, of an F-T Group III base oil having less than 5 wt % cycloparaffins, the balance of the blend being a Group III base oil having at least 35 wt % cycloparaffins. The finished lubricating compositions comprise a major amount of the base oil blend of the invention and at least one engine oil additive. | 2009-02-26 |
20090054286 | Liquid skin cleanser with multiple signals of adequate wash duration with adequate mechanical force - A personal cleansing composition includes a carrier, and a first plurality of beads entrained in the carrier. The beads impart, to a user applying the cleansing composition with hand rubbing force, perceivable tactility for a limited predetermined duration that corresponds to a minimum adequate cleansing time period. In accordance with another embodiment of the present invention, the personal cleansing composition further includes a second plurality of beads entrained in the carrier. The second plurality of beads imparts to the user a perceivable change in color for the cleansing composition for a second limited predetermined duration that is substantially equal to the duration that the tactility imparted by the first plurality of beads is perceivable to the user. | 2009-02-26 |
20090054287 | CLEANING COMPOSITIONS WITH WATER INSOLUBLE CONVERSION AGENTS AND METHODS OF MAKING AND USING THEM - The present invention relates to cleaning compositions comprising conversion agents and methods of using them. The conversion agents of the present invention comprise water insoluble compounds such as metal oxides, metal hydroxides, and combinations thereof. The compositions can be substantially free of a builder, e.g., a chelating agent, sequestrant, and/or threshold agent, while still achieving effective soil removal, and reduced spotting, scaling or combinations thereof. | 2009-02-26 |
20090054288 | Cleaning solvent for silicone caulk - A joint area formed by intersecting surfaces is provided with a caulk seal using a conventional caulking gun to apply an initial bead of silicone-based caulk to the joint. Thereafter, a spray of cleaning solvent is immediately applied to the caulk bead and the surrounding surfaces of the joint area to provide complete covering. Excess caulk is removed from the joint such as through finger wiping, to provide a smoothed caulk joint corner. A cloth fiber patch is soaked to saturation in cleaning solvent and is smoothly stroked across the smoothed joint surface to further finish the caulk material surface and to remove traces of excess caulk material from the adjoining or intersecting surfaces. In an exemplary embodiment, the cleaning solvent is used to caulk a tub and wall joint area of a typical bathroom facility and includes a formula of soft distilled water, glycol ether DPM, a surfactant and an antifoaming agent. | 2009-02-26 |
20090054289 | Bleach Systems Enveloped with Polymeric Layers - The invention relates to a bleach system comprising at least one component selected from bleach, bleach activator or bleach catalyst, wherein the bleach system is enveloped with at least one polymer layer and the polymer has urethane and urea groups. | 2009-02-26 |
20090054290 | MG++ CHEMISTRY AND METHOD FOR FOULING INHIBITION IN HEAT PROCESSING OF LIQUID FOODS AND INDUSTRIAL PROCESSES - The present invention relates to methods for removing or preventing scale formation in a liquid food processing operation. The present invention also relates to methods and compositions for increasing the solubility of insoluble calcium salts in an acidic environment. Aqueous antiscalant solutions comprising soluble magnesium salts are used to prevent the precipitation of insoluble calcium salts and/or to increase the solubility of insoluble calcium salts. | 2009-02-26 |
20090054291 | Soil Releasing Agent for Fiber - The invention provides a soil releasing agent for fiber, including a polymer having a weight-average molecular weight in a range from 2,000 to 30,000, and containing a structural unit (A) and a structural unit (B) the content of the structural unit (A) in the polymer being 50 to 99 percent by weight, and the content of the structural unit (B) in the polymer being 1 to 50 percent by weight: (A) a structural unit derived from a monomer which has an unsaturated bond and at least one amino group selected from a primary amino group, a secondary amino group and a tertiary amino group; (B) a structural unit derived from a monomer which has an unsaturated bond and at least one hydrophobic group selected from the group consisting of an alkyl or alkenyl group, each having 4 to 22 carbon atoms, being straight, branched or cyclic, an arylalkyl group having 1 to 22 carbon atoms in the alkyl group and an aryl group, and which monomer has no primary to tertiary amino group and then a method for treating fiber is conducted in an aqueous solution which contains the soil release agent and is adjusted to pH 2 to 9. | 2009-02-26 |
20090054292 | Encapsulated phthalocyanine granulates - The present invention relates to encapsulated granulates of phthalocyanine compounds wherein the encapsulating layer consists of at least one finely particulate solid and at least one hydrophobic coating material, to a process for the preparation thereof, and to washing agent formulations comprising such granulates. | 2009-02-26 |
20090054293 | BLEACH COMPOSITIONS - Laundry or cleaning composition comprising: (a) a catalytically effective amount, preferably from about 1 ppb to about 99.9%, of a transition-metal bleach catalyst which is a complex of a transition-metal and a cross-bridged macropolycyclic ligand; and (b) at least about 0.1% of one or more laundry or cleaning adjunct materials, preferably comprising an oxygen bleaching agent. Preferred compositions are laundry compositions and automatic dishwashing detergents which provide enhanced cleaning/bleaching benefits through the use of such catalysts. | 2009-02-26 |
20090054294 | LOW CARBON FOOTPRINT COMPOSITIONS FOR USE IN LAUNDRY APPLICATIONS - Liquid laundry detergent compositions are provided that show remarkable performance even though they utilize only eco-friendly ingredients and have a sustainability index of greater than 3. Some embodiments include a liquid laundry detergent composition comprising alkyl polyglycoside (APG) with fatty alcohol sulfate, at least two detersive enzymes, an enzyme stabilization system (e.g. borate and/or citrate and/or calcium salts), d-limonene or other natural essence, water and adjuvant. In another exemplary embodiment, APG is combined with fatty acid soaps, at least two detersive enzymes, an enzyme stabilization system (e.g. borate and/or citrate and/or calcium salts), d-limonene or other natural essence, water and adjuvant. Such compositions show remarkable performance, good viscosity, physical storage stability, enzyme stability, and have a sustainability index of greater than 3. | 2009-02-26 |
20090054295 | Chemical Delivery Product And Process For Making The Same - A chemical delivery product for delivering an oxidizing chemical into an aqueous system is disclosed. For instance, in one embodiment, a substrate containing an oxidizing chemical, such as trichloroisocyanuric acid, is coated with a water soluble polymer in order to prevent the oxidizing chemical from degrading prior to use and in order to facilitate handling. In accordance with the present disclosure, a neutralizing agent is contacted with the substrate in order to prevent the substrate from degrading the water soluble coating. In an alternative embodiment, a package is formed from a water soluble film forming composition combined with a base. | 2009-02-26 |
20090054296 | Fabric conditioning compositions - The concentrated liquid fabric softening composition of the present invention comprises an ester-linked triethanolamine (TEA) quaternary ammonium fabric softening material having an Iodine Value of between 0 and 60 and comprising a mixture of at mono-, di- and tri-ester linked components; a single long chain cationic surfactant based on quaternized fatty acid amido-amine surfactants with optional ethoxylate groups and preferably having a methylsulphate counter-ion; and a co-fragmenting agent which is a polyol selected from trihydric and polyhydric polyols. | 2009-02-26 |
20090054297 | Fabric conditioning compositions - The concentrated liquid fabric softening composition of the present invention comprises an ester-linked triethanolamine (TEA) quaternary ammonium fabric softening material having an Iodine Value of between 0 and 60 and comprising a mixture of at mono-, di- and tri-ester linked components; a single long chain cationic surfactant which has one or more ethoxylate groups and preferably has a methylsulphate counter-ion, and a co-fragmenting agent which is a polyol selected from trihydric and polyhydric polyols. | 2009-02-26 |
20090054298 | Thickening surfactants for acidic solutions - The invention is a thickened aqueous acid solution wherein the thickener is an aliphatic or alicyclic betaine of the formula | 2009-02-26 |
20090054299 | USE OF UNSATURATED KETONES AS A PERFUME - Unsaturated ketones of general formula (I) where the groups R1, R2, R3, R4 and R5 independently=H or 1-6 C alkyl groups, which can be saturated or unsaturated, straight-chained, branched or cyclic are characerised by an interesting and original odour characteristic with good emanation and are suitable for use as perfumes, for example in cosmetic preparations, technical products or alcoholic perfumery. | 2009-02-26 |
20090054300 | Compositions and Methods for the Treatment of Systemic Lupus Erythematosis - The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases | 2009-02-26 |
20090054301 | HYPOALLERGENIC COMPOSITION - This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal (including pet) consumption, and particularly hypoallergenic compositions, and more particularly semi-solid hypoallergenic compositions and hypoallergenic compositions that comprise a hydrolysate. This invention also is directed generally to methods for using such compositions. This invention is further directed generally to processes for making such compositions. | 2009-02-26 |
20090054302 | Methods and Preparations For Curing Clinically Ill Patients - This invention relates to a life saving medicament for critically ill patients and a method of treatment. The composition is a pharmaceutically effective amount of a blood glucose regulator which is used to control the blood glucose level. | 2009-02-26 |
20090054303 | CRYSTAL FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING SAME - Physical crystal structures of a compound of the formula I: | 2009-02-26 |
20090054304 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE - The present invention relates to compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. | 2009-02-26 |
20090054305 | Mixtures of Amylin and Insulin - The present invention relates to a soluble pharmaceutical composition for parenteral administration, which comprises an amylin peptide, and a meal-related insulin peptide, and to the use of such compositions for treatment of e.g. hyperglycemia. | 2009-02-26 |
20090054306 | Photodynamic therapy using chemiluminescence and a ligand-photosensitiser conjugate - A method for destroying harmful cells is provided, applicable in treating proliferative diseases. The cells are destroyed by a combined treatment with a chemiluminescent agent and with a ligand-photosensitizer conjugate. The chemiluminescent agent emits light on reacting with oxygen species present in situ, the conjugate binds to the cell through its ligand and is activated by the emitted light, thereby destroying the cell. The method is demonstrated on a conjugate of transferrin-hematoporphyrin, which destroys cancerous cells in the presence of luminol. | 2009-02-26 |
20090054307 | PROPHYLACTIC AND THERAPEUTIC AGENTS AND USES THEREFOR - Treatment, detection and monitoring of disease of the nervous system, especially trauma or hypoxia, in particular in the central nervous system and the eye by up-regulation or increasing levels of Ndfip1 (also known as Nedd4-WW Domain Binding Protein 5 or N4WBP5). Prophylaxis of such conditions in pre-term infants, coronary artery bypass graft, chemotherapy, tumor irradiation and other patients. | 2009-02-26 |
20090054308 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders - Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and at least one other active pharmaceutical ingredient to patient in need thereof. Pharmaceutical formulations are also disclosed. | 2009-02-26 |
20090054309 | Peptidic vasopressin receptor agonists - The present invention relates to novel compounds, pharmaceutical compositions comprising the same, use of said compounds for the manufacture of a medicament for treatment of inter alia shock conditions as well as to a method for treatment of said conditions, wherein said compounds are administered. The compounds are represented by the general formula (I), as further defined in the specification. | 2009-02-26 |
20090054310 | Method for Maximizing Efficacy and Predicting and Minimizing Toxicity of Calcineurin Inhibitor Compounds - The invention provides methods for predicting toxicity related to calcineurin inhibition therapy by measuring the peak concentration of drug and the trough concentration of the drug, calculating a peak-trough fluctuation, and comparing this peak-trough fluctuation to known values to predict if the patient will exhibit calcineurin-inhibition therapy-related toxicity. The invention also provides methods for monitoring drug levels to ensure that a patient receiving calcineurin inhibition therapy remains within a therapeutic window which maximizes the efficacy and minimizes the toxicity of the calcineurin inhibitor. The invention also provides dosage methods which maximize the peak concentration, minimize the trough concentration, and maximize the fluctuation between peak and trough concentration of calcineurin inhibitors, to maximize the efficacy of the calcineurin inhibition therapy, and minimize the risk of developing calcineurin-inhibition therapy-related toxicity. This dose regimen, which may be a once-daily dose regimen, maximizes efficacy associated with peak concentrations of drug and minimizes toxicity by maximizing the peak-trough fluctuation, a measurement determined to be associated with toxicity. Calcineurin inhibitors useful for these methods include members of the cyclosporin family of compounds, including cyclosporin A and ISA247, FK506, pimecrolimus and ascomycin. | 2009-02-26 |
20090054311 | Novel Cyclosporin Analog Formulations - The present invention relates to formulations containing cyclosporin analogs that are structurally similar to cyclosporin A, in particular isomeric mixtures of cyclosporin analogs that are structurally similar to cyclosporin A. The formulations form stable microemulsion preconcentrates and may provide superior drug bioavailability and/or may reduce one or more adverse effects associated with the administration of cyclosporin. Also disclosed are methods for using and preparing the formulations. | 2009-02-26 |
20090054312 | SMIPs: Small molecule inhibitors of p27 depletion in cancers and other proliferative diseases - Methods are provided for screening for SMIPs (small molecule inhibitors of p27 depletion). The SMIPs thus identified are useful for treating cancers and other proliferative diseases. | 2009-02-26 |
20090054313 | METHOD FOR INDUCING DEPOSITION AND MATURATION OF BONE COMPRISING A CO-THERAPEUTIC REGIMEN OF LMP-1 AND BMP-2 - The present invention relates to the methods and compositions for the treatment of subjects having compromised bone conditions. Specifically, the invention relates to combinatorial therapeutic strategies including small molecules and peptide mimics of LIM mineralization proteins, particularly LMP-1, to overcome the dose-related translational barriers for BMP-2 therapeutics. | 2009-02-26 |
20090054314 | Combined use of DPP-IV inhibitors and gastrin compounds - The invention relates to compositions, conjugates, and methods for the prevention and/or treatment of a condition and/or disease comprising a therapeutically effective amount of a DPP-IV inhibitor and a gastrin compound. The combination of a DPP-IV inhibitor and a gastrin compound provides beneficial effects, in particular sustained beneficial effects, in the prevention and/or treatment of conditions and/or diseases for which either a DPP-IV inhibitor or a gastrin compound have been demonstrated to have a therapeutic effect, including but not limited to diabetes, hypertension, chronic heart failure, fluid retentive states, obesity, metabolic syndrome and related diseases and disorders. Combinations of a DPP-IV inhibitor and a gastrin compound can be selected to provide unexpectedly additive effects or synergistic effects. | 2009-02-26 |
20090054315 | Counteracting Drug-Induced Obesity Using GLP-1 Agonists - The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug. | 2009-02-26 |
20090054316 | AGENT FOR CONTROL OF FUNCTION OF ANTIGEN-PRESENTING CELL - The present invention provides an agent capable of controlling the function of antigen-presenting cell. The present invention provides an agent for controlling the function of antigen-presenting cell, comprising a substance capable of controlling an intracellular zinc ion concentration, particularly, a zinc ion, a zinc ion chelator, a substance for regulating the expression and/or function of a zinc ion-requiring protein, or a substance for regulating the expression and/or function of a zinc ion transporter, as an active ingredient. | 2009-02-26 |
20090054317 | POLYVALENT INHIBITORS OF PATHOGENS - The present invention provides polyvalent host cell receptor-directed pathogen inhibitors and methods for designing and using such polyvalent inhibitors. Polyvalent inhibitors of the invention comprise a biocompatible scaffold having attached thereto a plurality of ligands, e.g. peptides, capable of binding a host cell receptor or portion thereof of a pathogen or toxin of a pathogen thereby preventing the pathogen or toxin thereof from binding to the host cell and causing toxicity of the host cell. Also provided are methods of designing such polyvalent host cell receptor-directed pathogen inhibitors and methods of using such inhibitors to prevent and/or treat infections of a host. The compositions of the inventions can be useful for treating anthrax. | 2009-02-26 |
20090054318 | Immunopotentiating Agent - Satisfactory effects have not always been attained by immunotherapy having been tried, and reliance upon direct attack on cells by anticancer agents, radiation, etc has been inevitable. The present invention intends to provide a therapeutic method that ensures less side effects but higher efficacy than in conventional therapeutic methods through enhancing of immune strength inherently had by living organism. Thus, the present invention relates to an immunopotentiating agent comprising MIP-1α or its functional derivative as an active ingredient. | 2009-02-26 |
20090054319 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders - The use of guanylin potentiating agents for treating various disorders, including hypertension as well as IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, chronic intestinal pseudo-obstruction, colonic pseudo-obstruction, Crohn's disease, duodenogastric reflux, dyspepsia, functional dyspepsia, nonulcer dyspepsia, a functional gastrointestinal disorder, functional heartburn, gastroesophageal reflux disease (GERD), gastroparesis, inflammatory bowel disease, irritable bowel syndrome, post-operative ileus, ulcerative colitis, chronic constipation, and disorders and conditions associated with constipation is described. | 2009-02-26 |
20090054320 | VESICULINS - The inventions relate generally to vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof, related compositions and formulations and their preparation and use, nucleic acids encoding such vesiculin peptides and vesiculin peptide chains, and fragments, variants and derivatives thereof and related vectors and host cells, hybridomas and antibodies, and methods for the prevention and treatment of conditions, diseases and disorders that would be improved, eased, or lessened by the administration of a composition of the invention, including but not limited to glucose metabolism diseases. | 2009-02-26 |
20090054321 | Polypeptides and use thereof - An isolated polypeptide comprises an amino acid sequence of SEQ ID No. 1 or 2 or a variant or fragment thereof. The variant may comprise an amino acid sequence that is at least 70% or 95% identical to the amino acid sequence of SEQ ID No. 1 or 2. A fragment thereof may be a peptide comprising at least 12 contiguous amino acids of SEQ ID No. 1 or 2. The polypeptide exhibits toll-like receptor activity. The TLR has been named TLR1 4. TLR receptors recognise a range of ligands and activate a series of signalling pathways that lead to the induction of immune and inflammatory genes. | 2009-02-26 |
20090054322 | Polypeptides and compositions comprising same and methods of using same for treating cxcr4 associated medical conditions - An isolated polynucleotide is provided, comprising a nucleic acid sequence encoding a soluble polypeptide which comprises an amino acid sequence of an N-terminus domain of CXCR4 and devoid of a CXCR4 extracellular domain selected from the group consisting of ECL1, ECL2 and ECL3, the soluble polypeptide being capable of binding SDF-1. Also provided are methods of using such a nucleic acid sequence such as for the treatment of cancer. | 2009-02-26 |
20090054323 | Specific Binding Agents of Human Angiopoietin-2 - Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies. | 2009-02-26 |
20090054324 | Transcriptional Regulation of High Affitnity Ige Receptor Gamma-Chain - Transcriptional regulatory regions and transcriptional regulatory factors for the human high affinity IgE receptor (FcεRI) γ-chain gene are specified and are targets for the development of transcriptional regulatory agents for the FcεRI γ-chain gene. The following are provided: DNA comprising the full length or a portion of the base sequence shown in SEQ ID NO:1, that regulates transcription of the human high affinity IgE receptor (FcεRI) γ-chain gene; and DNA comprising the full length or a portion of the base sequence shown in SEQ ID NO:2, that regulates transcription of the human high affinity IgE receptor (FcεRI) γ-chain gene. The present invention is promising for the development of novel agents for the prophylaxis/treatment of allergic diseases, autoimmune diseases, thrombosis, glomerulonephritis, and lupus nephritis. | 2009-02-26 |
20090054325 | Compositions and methods for suppressing axonal growth inhibition - The invention provides compositions and methods for interfering with Nogo-receptor mediated signaling and mediating axonal growth. The invention also provides methods for treating central nervous system diseases, disorders or injuries. | 2009-02-26 |
20090054326 | FORMULATIONS FOR ENHANCED MUCOSAL DELIVERY OF PYY - Pharmaceutical formulations are described for enhancing mucosal delivery of peptide YY (PYY) to a mammal. A PYY dosage form is described that is suitable for multi-use administration. The PYY dosage form comprises a bottle containing an aqueous pharmaceutical formulation and an actuator effective intranasal administration of the formulation. The formulation comprises a therapeutically effective amount of PYY, a buffer to control pH, a water-miscible polar organic solvent and a chelating agent for cations. The PYY dosage form exhibits at least 90% PYY recovery after storage as used for greater than about five days. | 2009-02-26 |
20090054327 | TAT-utrophin as a protein therapy for dystrophinopathies - Disclosed is a fusion protein including a full-length TAT-utrophin or an anti-dystrophinopathic fragment thereof, a method of treating dystrophinopathies (including Duchenne muscular dystrophy) using the fusion protein, a pharmaceutical composition for treating treating dystrophinopathies in mammals comprising the fusion protein, and nucleic acid constructs for expressing the fusion protein. | 2009-02-26 |
20090054328 | Reagents and Methods for Modulating Gene Expression Related to Hypertension - This invention relates to gene expression and proliferation in eukaryotic, preferably mammalian and most preferably human cells. The invention specifically relates to hypertension associated with proliferation and contractility of vascular smooth muscle cells. | 2009-02-26 |
20090054329 | COMPOSITION WITH DOCOSAPENTAENOIC ACID - This invention concerns a method for stimulating barrier integrity in a subject by administering to a subject a composition comprising docosapentaenoic acid (22:5 n3; DPA). Also the invention concerns a composition comprising DPA and eicosapentaenoic acid (EPA). | 2009-02-26 |
20090054330 | Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection - The present invention provides a method of blocking xenograft rejection in a patient in need of such treatment by administering to said patient a virally-encoded complement control protein, referred to as the inflammation modulatory protein (IMP). The present invention further provides pharmaceutical compositions for the prevention or treatment of xenograft rejection comprising the IMP protein, alone or in combination with other immunosuppressive agents. | 2009-02-26 |
20090054331 | HIGH TEMPERATURE STABLE PEPTIDE FORMULATION - A stabilized pharmaceutical composition in the form of a lyophilized product to be later reconstituted to generate an aqueous drug product is described herein. The therapeutically active ingredient in the form of a peptide of sequence TDLQERGDNDISPFSGDGQPFKD is stabilized with a buffer, carbohydrate stabilizer, a nonionic bulking agent and a surfactant to facilitate reconstitution. The preferred preparation contains a peptide of the sequence TDLQERGDNDISPFSGDGQPFKD, histidine buffer, mannitol or glycine, sucrose and/or Polysorbate 20. This combination of excipients has demonstrated exceptional stability as a lyophilized product when stored at the elevated temperature of 40° C. for at least 6 months and for at least 3 Months at 50° C. The lyophilized mixture thus formed is reconstituted to a high peptide concentration without apparent loss of stability of the peptide. Also, this combination of excipients has also enabled the ability to terminally sterilize the lyophilized product using gamma irradiation without affecting the stability of the active ingredient of the formulation. | 2009-02-26 |
20090054332 | THOMBOPOIETIN PEPTIDE CONJUGATES - The present invention relates to compounds comprising modified thrombopoietin peptides and conjugates of such modified peptides to serum components, typically serum proteins or peptides. The compounds and conjugates of the invention comprise a reactive group or a residue of a reactive group, which is covalently attached to a modified peptide, optionally through a linking group. The present invention also provides methods for the covalent attachment of a modified peptide to a serum protein or peptide to form a conjugate of the invention. The conjugates of the invention typically exhibit a longer in vivo circulating half-life compared to the corresponding unconjugated peptides. The conjugates of the invention also retain at least some of the biological activity of the unconjugated peptides, and typically exhibit increased biological activity compared to the unconjugated peptides. The present invention also provides methods for the treatment and prevention of a disease or disorder comprising the administration of one or more of the compounds or conjugates of the invention to a subject in need of such treatment or prevention. | 2009-02-26 |
20090054333 | Peptide inhibitors of cyclin-dependent kinase activity and uses thereof - Novel polypeptides or derivatives comprising cdk2 binding site are disclosed. The novel polypeptides or derivatives have growth suppressive activity. Nucleic acids encoding those polypeptides are also disclosed. The polypeptides identified herein are also useful in methods for treating or preventing cancer. The treatment methods comprise administration of the polypeptide to the patient. The methods also comprise contacting the sample with the above-described polypeptide or derivative, wherein the polypeptide or derivative also comprises a covalently attached detectable moiety, then determining whether the polypeptide or derivative is binding cdk2 from the sample. | 2009-02-26 |
20090054334 | Combinatorial improvement of bifunctional drug properties - A method is provided for improving at least one pharmacokinetic property and maintaining or improving affinity of a therapeutic upon administration to a host. In the method, one administers to the host an effective amount of a bifunctional compound of less than about 5000 Daltons comprising the therapeutic or an active derivative, fragment or analog thereof and a recruiter ligand moiety. The recruiter ligand moiety binds to at least one biomoiety. The bifunctional compound has at least one modulated pharmacokinetic property upon administration to the host and equivalent or greater affinity for a target of the therapeutic as compared to a free drug control that comprises the therapeutic. In addition, the overall drug efficacy is improved by the steric bulk of the bifunctional complexed with the recruited biomoiety. | 2009-02-26 |
20090054335 | AXMI-028 AND AXMI-029, A FAMILY OF NOVEL DELTA-ENDOTOXIN GENES AND METHODS FOR THEIR USE - Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also comprise transformed bacteria, plants, plant cells, tissues, and seeds. In particular, isolated delta-endotoxin nucleic acid molecules are provided. Additionally, amino acid sequences corresponding to the polynucleotides are encompassed. In particular, the present invention provides for isolated nucleic acid molecules comprising nucleotide sequences encoding the amino acid sequence shown in SEQ ID NO:2, 4, 15, 17, or 19, or the nucleotide sequence set forth in SEQ ID NO:1, 3, 14, 16, or 18, as well as variants and fragments thereof. | 2009-02-26 |
20090054336 | Binding Agent - Agents which bind to cell surface receptors; methods to manufacture such agents; therapeutic compositions comprising such agents; and screening methods to identify novel agents. | 2009-02-26 |
20090054337 | NATRIURETIC POLYPEPTIDES - This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal. | 2009-02-26 |
20090054338 | Synergisms between repartitioning and immunomodulating compounds - Combination therapies of adrenergic beta-receptor agonists and beta-glucans are described. | 2009-02-26 |
20090054339 | Novel cellular factor-containing solution compositions - The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof. | 2009-02-26 |
20090054340 | Use of heat-shock protein 27 for cardiovascular disease prevention and treatment - A method of preventing or treating cardiovascular disease is provided. The method comprises administering heat shock protein 27 (HSP27), a co-factor, variant or analogue thereof. The cardiovascular disease can include atherosclerosis. A pharmaceutical composition comprising HSP27 for use in the prevention or treatment of cardiovascular disease is also provided. | 2009-02-26 |
20090054341 | Methods of Treatment Using Exendin Peptides or GLP-1 Peptides - Methods for increasing urine flow are disclosed, comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. Methods for increasing urinary sodium excretion and decreasing urinary potassium concentration are also disclosed. The methods are useful for treating conditions or disorders associated with toxic hypervolemia, such as renal failure, congestive heart failure, nephrotic syndrome, cirrhosis, pulmonary edema, and hypertension. The present invention also relates to methods for inducing an inotropic response comprising administration of an effective amount of GLP-1, an exendin, or an exendin or GLP-1 agonist. These methods are useful for treating conditions or disorders that can be alleviated by an increase in cardiac contractility such as congestive heart failure. Pharmaceutical compositions for use in the methods of the invention are also disclosed. | 2009-02-26 |
20090054342 | Bioactive peptides and method of using same - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 2009-02-26 |
20090054343 | Methods of therapy using pharmaceutical composition for thrombin peptide derivatives - Disclosed are pharmaceutical compositions comprising a thrombin peptide derivatives and a chelating agent and/or a pharmaceutically acceptable thiol-containing compound. The pharmaceutical compositions optionally further comprise an antioxidant. Also, disclosed are methods for activating the non-proteolytically activated thrombin receptor in a subject in need of such treatment. The methods comprise the step of administering an effective amount of a thrombin peptide derivative in the pharmaceutical composition described above. | 2009-02-26 |
20090054344 | ANTI-ANGIOGENIC PROTEINS AND FRAGMENTS AND METHODS OF USE THEREOF - Proteins with anti-angiogenic properties are disclosed, and fragments thereof, and methods of using those proteins and fragments to inhibit or promote angiogenesis. | 2009-02-26 |
20090054345 | Template-Fixed Beta-Hairpin Peptidomimetics With Protease Inhibitory Activity - Templates-fixed β-hairpin peptidomimetics of the general formulae (I), wherein Z is a chain of 11α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or Pro(4NHCOPhe), or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to inhibit proteases, in particular serine proteases, especially Cathepsin G or Elastase or Tryptase. These β-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and solution phase synthetic strategy. | 2009-02-26 |
20090054346 | ELASTIN PRODUCTION-ENHANCING AGENTS - An objective of the present invention is to provide novel useful elastin production-enhancing agents that have a remarkable ability to enhance elastin production. The present invention provides elastin production-enhancing agents that include at least one component selected from the group consisting of the peptide Leu-Glu-His-Ala (formula I; SEQ ID NO:1), derivatives of the peptide, and salts thereof. The present invention also provides elastin production-enhancing agents that include at least one component selected from the group consisting of peptides which include a conservative substitution, deletion, and/or addition of one or more amino acids in the amino acid sequence of formula I that retain an ability to enhance elastin production in cells; derivatives of such peptides; and salts thereof. | 2009-02-26 |
20090054347 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF - The present invention provides for novel kinin B1 receptors peptide agonists of formula (I) having very good to excellent affinities and selectivity for the B | 2009-02-26 |
20090054348 | BI-DENTATE COMPOUNDS AS KINASE INHIBITORS - The present invention provides compound having the general structure A or pharmaceutically acceptable salts thereof: | 2009-02-26 |
20090054349 | Peptides for Promoting Hair Growth and Improving Wrinkle and Cosmetic Compositions Comprising the same - The present invention relates to a peptide comprising a specific amino acid sequence possessing human thymosin β-4 (Tβ4) activities and its uses. The peptide of this invention has identical or similar functions or actions to human Tβ4 and its biological activity is almost identical to natural-occurring Tβ4. In addition, the peptide of this invention exhibits much higher stability and skin permeation than natural-occurring Tβ4. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in thymosin β-4-effective disorders or conditions. In addition, the peptide of this invention can be advantageously applied to drugs, cosmetics, toothpaste and compositions for mouth cleaning and caring, most preferably, cosmetics. Specifically, the peptide of this invention is advantageously applied to cosmetics for promoting hair growth. | 2009-02-26 |
20090054350 | PROCESS FOR THE STERILE CONCENTRATION OF COLLAGEN PREPARATIONS, AND COLLAGEN PREPARATIONS OBTAINED - The invention relates to a process for the preparation of sterile collagen, especially injectable collagen, comprising the steps of preparing a purified acidic collagen solution, filtering that solution through a filter or a sterile membrane, precipitating the filtered solution in the form of a suspension, and concentrating the collagen suspension, in which process the suspension is placed in an elongate supple tubular filter constituting a porous filtering wall, permeable to the liquid but not permeable to the collagen fibres, and is concentrated by the slow passage of the liquid through the wall, without any pressure other than gravity, in order to prevent the filtering wall from becoming clogged by the collagen fibres, optionally with absorption of the liquid by an absorbent layer covering the wall or forming part of that wall, and the subsequent flowing-away and/or evaporation of the liquid via the face of the layer remote from the wall, and collagen preparations obtained. | 2009-02-26 |
20090054351 | COMPOSITION FOR MODERATING ALCOHOL METABOLISM AND FOR REDUCING THE RISK OF ALCOHOL INDUCED DISEASES - The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer's disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases. In this respect, the present invention is also directed to a composition of matter; in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively, which supports and/or moderates the alcohol degradation process within the human body. | 2009-02-26 |
20090054352 | BENZENE DERIVATIVE OR SALT THEREOF - Problem: To provide compounds which have an anticoagulation effect based on their ability to inhibit the activated blood coagulation factor X and are useful as coagulation inhibitors or agents for prevention or treatment for diseases caused by thrombi or emboli. | 2009-02-26 |
20090054353 | MANNOSYL-1 PHOSPHATES, PREPARATION METHOD AND THERAPEUTIC USE, IN PARTICULAR AGAINST THE CDG-IA SYNDROME - The present invention relates, as medicaments, to the α-D-mannopyranosyl-1 phosphate derivatives of formulae I, II and III: | 2009-02-26 |
20090054354 | DRUG AND FOOD OR DRINK FOR IMPROVING PANCREATIC FUNCTIONS - Compounds having a cyclolanostane skeleton such as 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan-3-ol are used as an active ingredient of a drug and food or drink for improving pancreatic functions. | 2009-02-26 |
20090054355 | Proliferation Inhibitor Of Helicobacter Pylori Including Alpha-N-Acetyl-Glucosaminyl Bond-Containing Monosaccharide Derivatives - The present invention herein provides a proliferation inhibitor of Helicobacter pylori comprising a compound that can simply be mass-produced, can specifically inhibit the proliferation of H. pylori, which has high safety and never generates any resistant bacteria, as well as a diet of a food or beverage, and a pharmaceutical preparation containing the proliferation inhibitor of Helicobacter pylori. The proliferation inhibitor of Helicobacter pylori comprises an alpha-N-acetyl-glucosaminyl bond-containing monosaccharide derivative represented by the following chemical formula (1) | 2009-02-26 |
20090054356 | 1-SUBSTITUTED-7-(B-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME - [Objective] The present invention provides a compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity or the like.
| 2009-02-26 |
20090054357 | MACROLIDE COMPOUNDS ENDOWED WITH ANTIINFLAMMATORY ACTIVITY - Macrolide compounds endowed with antiinflammatory activity are described, and more particularly macrolide derivatives lacking cladinose in position 3, with antiinflammatory activity, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them as active ingredient. | 2009-02-26 |
20090054358 | Flt3 inhibitors for immune suppression - New methods are provided for suppressing the immune system and for treating immune related disorders. Therapies of the invention include administration of an FLT3 inhibitor compound to a subject in need thereof, such as a subject suffering from organ rejection, bone marrow transplant rejection, acquired immune deficiency syndrome, arthritis, aplastic anemia, graft-versus-host disease, Graves' disease, established experimental allergic encephalitomyelitis, multiple sclerosis, lupus, or a neurological disorder. Methods are also provided for screening therapeutic agents for treating immune disorders, including the use of a mouse having an elevated level of FLT3 receptor activity. | 2009-02-26 |
20090054359 | COMPOSITIONS AND THEIR USES DIRECTED TO DIACYLGLYCEROL ACYLTRANSFERASE 1 - Disclosed herein are compounds, compositions and methods for modulating DGAT-1 activity. Preferably, the expression of DGAT-1 from a nucleic acid is inhibited. Methods are provided for treating, ameliorating or treating liver fibrosis, either directly or by treating an underlying etiological factor. Preferably, the treatment, amelioration or prevention comprises administering a DGAT-1 activity modulator. | 2009-02-26 |
20090054360 | Method and Composition for Treating Allergic Diseases - A method and composition for treating allergic diseases and/or airway inflammation including pollinosis, bronchial asthma, allergic rhinitis, atopic dermatitis and anaphylactic shock with the administration to a subject an amount of an anti-infectious agent such as ribavirin and optionally combined with an anti-inflammatory agent selected from inhaled steroids, leukotriene receptor antagonists and beta- | 2009-02-26 |
20090054361 | Pot1 alternative splicing variants - The present invention provides methods an compositions for diagnosis and treatment of carcinomas with aberrant expression patterns of POT 1. The invention also provides methods of identifying compounds that may modulate the cellular expression of POT 1. The invention further provides methods for treating subjects suffering from or at risk of developing a colorectal carcinoma. | 2009-02-26 |
20090054362 | COMPOUNDS - The present invention provides novel aptamer derivatives which are useful in binding to and neutralising viruses. Pharmaceutical formulations comprising the aptamers and the use of the aptamers in screening for useful compounds are also provided. | 2009-02-26 |
20090054363 | Genetic markers and methods for detecting and treating cancers - The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and/or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue. Furthermore, the identified genetic marker SOX5 and/or SPARC can also be used for cancer targeted therapy, because down regulation of SOX5 and/or up regulation of SPARC expression in NOD-SCID can retard tumor growth and inhibit cell proliferation, migration, invasion and metastasis. | 2009-02-26 |
20090054364 | Methods and compositions for delivery of pharmaceutical agents - Methods and compositions for delivering pharmaceutical agents into cells, in particular urothelial cells of the bladder, are provided. In the methods and compositions of the invention, a solubilized cholesterol composition is used to facilitate delivery of pharmaceutical agents. Preferably, the cholesterol is solubilized by a cyclodextrin (e.g., methyl-β-cyclodextrin) and the pharmaceutical agent comprises a polynucleotide and either a cationic lipid, a cationic polymer or a dendrimer. Improved methods for transfecting polynucleotides into cells thus are also provided, using cationic lipids, cationic polymers or dendrimers and solubilized cholesterol, wherein the transfection efficiency is enhanced compared to use of cationic lipids, cationic polymers or dendrimers alone. Preferred methods of the invention involve transfecting polynucleotides into urothelial cells, preferably for therapeutic treatment of bladder cancer using, for example, a polynucleotide(s) encoding an interleukin(s), an interferon(s), a colony stimulating factor(s) and/or a tumor suppressor(s). | 2009-02-26 |
20090054365 | RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF OCULAR NEOVASCULARIZATION - RNA interference is provided for inhibition of aquaporin 1 (AQP1) to treat conditions associated with neovascularization. | 2009-02-26 |
20090054366 | RNAi MEDIATED KNOCKDOWN OF NUMA FOR CANCER THERAPY - This invention relates to the use of short interfering nucleic acid molecules (siRNA) to inhibit Nuclear Mitotic Apparatus Protein (NuMA) gene expression and their use in treatment of disease, including cancer. | 2009-02-26 |
20090054367 | MYCOBACTERIAL ANTIGENS EXPRESSED UNDER LOW OXYGEN TENSION - A method is provided for identifying mycobacterial genes that are induced or up-regulated under continuous culture conditions defined by a dissolved oxygen tension of up to 10% air saturation measured at 37° C. when compared with a dissolved oxygen tension of at least 40% air saturation measured at 37° C. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection. | 2009-02-26 |
20090054368 | Substituted gemini surfactant compounds - The compositions, systems, and methods relate to substituted and asymmetric gemini surfactants for use in delivering biologically active agents, such as nucleic acids, to a subject. The described compositions, systems, and methods are useful for gene therapy. | 2009-02-26 |
20090054369 | PHARMACEUTICAL COMPOSITIONS OF SILICON-CONTAINING SUBSTITUTED ADENOSINE NUCLEOSIDE AMIDE ANALOGS - Novel compositions of silicon-containing anti-metabolite compounds, their preparation and use in methods for treating cancer are described. The silyl group confers lipophilicity that can enhance the penetration of the compounds across the gut wall, cell membranes and blood brain barrier, thus improving therapeutic properties including bioavailability, metabolism, and/or pharmacokinetics. The triorganosilyl group provides compounds having improved pharmacokinetics and anti-tumor activity. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for treatment of diseases and other maladies or conditions involving cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2009-02-26 |
20090054370 | PYRIMIDINES, SUCH AS URIDINE, IN TREATMENTS FOR PATIENTS WITH BIPOLAR DISORDER - The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder. | 2009-02-26 |
20090054371 | FOLIC ACID-, VITAMIN B6- AND VITAMIN B12-CONTAINING AGENTS AND THE USE THEREOF - The invention relates to agents containing a folic acid, vitamin B6 and vitamin B12 and to the use thereof in hyperhomocystenemia for controlling homocysteine levels. The inventive agents are particularly suitable for preventive and acute treatment of vascular diseases of pregnant women and neurodegenerative diseases and are particularly advantageous in cases of hyperhomocysteinemia whose treatment with homocysteine level reducing agents causes secondary effects. Pharmaceutical agents and food supplements comprising the corresponding active substance combination, agents in the form of commercial packages containing corresponding combination preparations or monopreparations for a combined application are, in particular, also disclosed. | 2009-02-26 |
20090054372 | Combination therapy for weight loss - The present invention is directed to methods and kits for achieving or maintaining weight loss. These kits and methods can include administering a pharmaceutical composition comprising phentermine, topiramate and a B vitamin to a subject in need thereof. | 2009-02-26 |
20090054373 | CHITIN DERIVATIVES FOR HYPERLIPIDEMIA - The preferred embodiments relate to chitin derivatives for prevention or treatment of hyperlipidemia, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The preferred embodiments are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. | 2009-02-26 |
20090054374 | METHODS OF TREATING ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention provides methods for treating and preventing acute exacerbations of Chronic Obstructive Pulmonary Disease. The methods particularly comprise administering to a patient have COPD a composition comprising O-desulfated heparin. The administration can be after onset of one or more symptoms indicating an exacerbation of COPD or prior to onset of such symptoms. After onset of an acute exacerbation, administration of the O-desulfated heparin is particularly beneficial for reducing the time of hospitalization of the patient and for reducing lung inflammation. | 2009-02-26 |
20090054375 | Compositions, Systems, and/or Methods Involving Chlorine Dioxide - Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. When stored, a concentration of the chlorine dioxide in the composition of matter can be retained, with respect to an initial concentration of chlorine dioxide in said composition of matter, at, for example, greater than 12% for at least 14 days. Certain exemplary embodiments can provide a method comprising releasing chlorine dioxide from a solid composition comprising chlorine dioxide complexed with a cyclodextrin. | 2009-02-26 |
20090054376 | BENZOFURAN DERIVATIVES WITH THERAPEUTIC ACTIVITIES - The present invention relates to novel benzofuran compounds, to pharmaceutical compositions that include such compounds, and to methods of use thereof. Certain compounds of the invention share some pharmacological properties with cannabinoids and have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are useful as analgesic, neuroprotective, immunomodulatory and anti-inflammatory agents. | 2009-02-26 |
20090054377 | COMPOSITIONS AND METHODS FOR SMOKING CESSATION - The invention discloses a method and a composition for smoking cessation or for promoting smoking cessation in individual smokers. The compositions described contain phosphatidic acid as the active ingredient. | 2009-02-26 |
20090054378 | IMMUNOMODULATORY COMPOUNDS AND TREATMENT OF DISEASES RELATED TO AN OVERPRODUCTION OF INFLAMMATORY CYTOKINES - Method of using immunomodulatory compounds for treating diseases related to an overproduction of inflammatory cytokines, including diseases selected from asthma, atopic dermatitis, allergic rhinitis, prostatitis, inflammatory bowel disease, diabetes, and rhumatoid arthritis, the compounds being of general formula (I): | 2009-02-26 |
20090054379 | 7-Pyrollyl 9-Aminoacyl Tetracycline Compounds and Methods of Use Thereof - A compound of formula (I): | 2009-02-26 |
20090054380 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection - The present invention relates to | 2009-02-26 |
20090054381 | METHODS FOR TREATING RESPIRATORY DISORDERS - The invention provides methods for treating respiratory disorders in a patient in need thereof comprising administering an effective amount of (i) at least one hydralazine compound or a pharmaceutically acceptable salt thereof, (ii) isosorbide dinitrate and/or isosorbide mononitrate, and (iii) optionally at least one therapeutic agent. The hydralazine compound may be hydralazine hydrochloride. The respiratory disorders may be chronic obstructive pulmonary disease, pulmonary hypertension, emphysema, asthma, cystic fibrosis and bronchitis. | 2009-02-26 |
20090054382 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS - Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV (“PDE-IV”), and at least one other active ingredients selected from muscarinic receptor antagonists (MRA), β2-agonists, p38 MAP Kinase inhibitors, and corticosteroids and optionally one or more pharmaceutically acceptable excipients and/or other therapeutic agents. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided. | 2009-02-26 |